(Q38652153)

5 September 2017

Current disease modifying approaches to treat Parkinson's disease (English)

1 reference

5 September 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

5

Natale Belluardo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

4

Giuseppa Mudò

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1

Dan Lindholm

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Johanna Mäkelä

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Ove Eriksson

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Mart Saarma

series ordinal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

publication date

30 November 2015

1 reference

Cellular and Molecular Life Sciences

5 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

1365-1379

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26616211%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00018-015-2101-1

8 June 2020

exact match

0 references

cites work

Genetics of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Mitochondrial biology and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

100 years of Lewy pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Basic science breaks through: New therapeutic advances in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Identification of synaptosomal proteins binding to monomeric and oligomeric α-synuclein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Glucocerebrosidase and Parkinson disease: Recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

No evidence for substrate accumulation in Parkinson brains with GBA mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Alpha-synuclein propagation: New insights from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Gut microbiota are related to Parkinson's disease and clinical phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

The unfolded protein response: from stress pathway to homeostatic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

ER stress and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

An ERcentric view of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

ER proteostasis disturbances in Parkinson's disease: novel insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

How do Parkin mutations result in neurodegeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

MAM: more than just a housekeeper

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

α-Synuclein is localized to mitochondria-associated ER membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Mitochondria: in sickness and in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Mitochondrial quality control: a matter of life and death for neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Disease-modifying strategies for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

PGC-1alpha: turbocharging mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

PGC-1α: a master gene that is hard to master

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Parkinson's disease, insulin resistance and novel agents of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Diabetes drugs and neurological disorders: new views and therapeutic possibilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Exenatide and the treatment of patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Neuroinflammation in the living brain of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Macrophage plasticity and polarization: in vivo veritas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

The therapeutic potential of interleukin-10 in neuroimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Microglia and inflammation: conspiracy, controversy or control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Plasma urate and risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Urate as a predictor of the rate of clinical decline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

The GDNF family: signalling, biological functions and therapeutic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Absolute requirement of GDNF for adult catecholaminergic neuron survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

GDNF is not required for catecholaminergic neuron survival in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Repairing the parkinsonian brain with neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Parkinson's disease gene therapy: success by design meets failure by efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

The Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

TGFbeta induces GDNF responsiveness in neurons by recruitment of GFRalpha1 to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Protective effect of platelet-derived growth factor against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Enhanced synthesis of platelet-derived growth factor following injury induced by 6-hydroxydopamine in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Can Parkinson's disease be cured by stimulating neurogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Preferential neurotrophic activity of fibroblast growth factor‐20 for dopaminergic neurons through fibroblast growth factor receptor‐1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

A specific survival response in dopamine neurons at most risk in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Growth factors and feeder cells promote differentiation of human embryonic stem cells into dopaminergic neurons: a novel role for fibroblast growth factor-20

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Fibroblast growth factor 20 polymorphism in sporadic Parkinson's disease in Northern Han Chinese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Cell biology. FGF21 takes a fat bite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Endocrine FGFs and Klothos: emerging concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

The fasting polypeptide FGF21 can enter brain from blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

The starvation hormone, fibroblast growth factor-21, extends lifespan in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

PACAP functions as a neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Differential signal transduction by five splice variants of the PACAP receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Activation of Trk neurotrophin receptor signaling by pituitary adenylate cyclase-activating polypeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

PACAP is an endogenous protective factor-insights from PACAP-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Interferon-gamma produced by microglia and the neuropeptide PACAP have opposite effects on the viability of neural progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Urate and neuroprotection trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-2101-1

Novel CDNF/MANF family of neurotrophic factors

21 January 2018

1 reference

12 December 2020

Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells

1 reference

12 December 2020

Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.

1 reference

12 December 2020

Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease.

1 reference

12 December 2020

Mechanism of action and in vivo role of platelet-derived growth factor

1 reference

12 December 2020

Neurotrophic and neuroprotective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on mesencephalic dopaminergic neurons

1 reference

12 December 2020

Unfolded protein response is activated in Lewy body dementias.

1 reference

12 December 2020

What causes cell death in Parkinson's disease?

1 reference

12 December 2020

MANF Is Indispensable for the Proliferation and Survival of Pancreatic β Cells

1 reference

12 December 2020

Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release

1 reference

12 December 2020

The genetics of Parkinson's disease

1 reference

12 December 2020

Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease.

1 reference

12 December 2020